Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT00184665
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT00184691
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT00184678
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 554
- Registration Number
- NCT00184548
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 708
- Registration Number
- NCT00184600
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 97
- Registration Number
- NCT00184626
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Efficacy on Height in SGA Children Treated With Growth Hormone
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 151
- Registration Number
- NCT00184756
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00184730
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT00184769
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 603
- Registration Number
- NCT00184574
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath